Business Wire

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s

Share

Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) today announced that following a re-examination procedure the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Parkinson’s is a chronic, progressive neurodegenerative condition that affects small regions in the brain that control movement, balance and posture.1 It is the fastest growing neurodegenerative disorder in the world.2

“We are disappointed by the CHMP opinion. We will take time to assess our plans for istradefylline in EMEA,” said Tomohiro Sudo, Executive Officer, Head of Global Product Strategy Department at Kyowa Kirin. “We appreciate the collaboration we have had with all stakeholders and applaud the Parkinson’s community for their commitment to supporting people living with this chronic, debilitating condition.”

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies. The company is committed to bringing our innovative therapies to patients.

About istradefylline

Istradefylline was developed as a novel, first-in-class non-dopaminergic, adenosine A2A receptor antagonist that reduces ‘OFF’ time in people living with Parkinson’s through selective targeting of adenosine A2A receptors in the basal ganglia. Whilst dopaminergic treatment targets the dopamine receptors in the direct and indirect pathways to facilitate movement, istradefylline, as an add-on to L-Dopa, reduces the activity of the indirect pathway which suppresses movement.3,4 Consequently, it helps restore the balance within the basal ganglia.1,2

About Parkinson’s and ‘OFF’ episodes

There are an estimated 10 million people in the world currently living with Parkinson’s.5 Although it is classically characterised by motor symptoms (symptoms involving movement), people living with the condition also experience a large range of non-motor symptoms, which add to the complexity of living with the condition.5 Although Parkinson’s is not life threatening there is currently no cure.1 Over time symptoms progress and can be unpredictable, imposing a significant impact on daily life.1 This impact can extend to caregivers, friends and family, whose own wellbeing and quality of life can deteriorate as a result.6

‘OFF’ episodes is used to describe the return of Parkinson’s symptoms, also known as ‘OFF’ symptoms, and can be triggered by a variety of phenomena, including:7

  • Delayed onset of response to medication
  • Reduced duration of benefit from a medication
  • Reduced or no efficacy of a dose of medication

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.

Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

Kyowa Kirin International

http://www.international.kyowa-kirin.com /

Galabank Business Park
Galashiels, TD1 1QH
United Kingdom

References


1. European Parkinsons Disease Association. About Parkinson’s, https://www.epda.eu.com/about-parkinsons/what-is-parkinsons/ [Last accessed Novemeber 2021].

2. Dorsey ER, Sherer T, Okun MS, et al. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 2018; 8: S3-s8. 2018/12/26. DOI: 10.3233/jpd-181474.

3. Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 963-972. 2013/07/03. DOI: 10.1007/s00210-013-0897-5.

4. LeWitt PA, Aradi SD, Hauser RA, et al. The challenge of developing adenosine A(2A) antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord 2020; 80 Suppl 1: S54-s63. 2020/12/23. DOI: 10.1016/j.parkreldis.2020.10.027.

5. Ball N, Teo W-P, Chandra S, et al. Parkinson's Disease and the Environment. Frontiers in Neurology 2019; 10. Mini Review. DOI: 10.3389/fneur.2019.00218.

6. Armstrong MJ, Rastgardani T, Gagliardi AR, et al. The impact of off periods on persons with Parkinson’s and care partners: a qualitative study. Neurol Clin Pract 2020;10.1212/CPJ.0000000000000921.

7. Freitas ME, Hess CW and Fox SH. Motor Complications of Dopaminergic Medications in Parkinson's Disease. Semin Neurol 2017; 37: 147-157. 2017/05/17. DOI: 10.1055/s-0037-1602423.

KKI/INT/IST/0142
Date of preparation: November 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for Kyowa Kirin International:
Media
Sarah Evans
Email: Sarah.Evans@kyowakirin.com

Contacts for Kyowa Kirin Co., Ltd.:
Media
Hiroki Nakamura
Email: media@kyowakirin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Digi International Unveils Connect EZ Family of Device Servers8.12.2021 16:00:00 EET | Press release

Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Connect EZ®, a next-generation family of device servers providing connectivity for business, commercial, and industrial automation applications. With the discovery and configuration tool Digi Navigator™ and Digi Accelerated Linux (DAL) operating system integration, Connect EZ leapfrogs outdated serial-interface designs to provide an easy-to-deploy, reliable and innovative solution that ensures longevity and manageability for connectivity applications in manufacturing, retail, medical, and telecom. “Companies are not replacing their equipment; they’re updating the way they talk to it,” says Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “Connect EZ modernizes serial connectivity with LTE and Wi-Fi options, enhanced manageability, security, intelligence and performance, while o

Prodapt Acquires UK-Based SLR Dynamics8.12.2021 15:21:00 EET | Press release

Prodapt, the leading consulting, technology & managed services provider to the Connectedness vertical, announced that it acquired SLR Dynamics, a UK-based company focused on digital engineering and automation services in the TMT industry. SLR Dynamics counts leading European and African telcos as their customers. This is Prodapt’s second acquisition for the year following its acquisition of Silicon Valley-based Innovative Logic in August. The acquisition of SLR Dynamics will strengthen Prodapt’s leadership position in the connectedness vertical. With the TMT industry accelerating digital transformation journeys using technologies like 5G, cloud, SDN/NFV, Edge Computing, IoT, and AI-ML, Prodapt’s acquisition of SLR Dynamics will help deliver enhanced value to its global customers. “I am excited to welcome Salim and the SLR Dynamics team to the Prodapt family,” said Vedant Jhaver, Chairman and CEO, Prodapt. “The capabilities of SLR Dynamics in Cloud, Security, IoT and Product design will

NielsenIQ Rises to the Omnichannel Measurement Challenge8.12.2021 15:01:00 EET | Press release

The shopper journey continually evolves as consumers have more control over what they do, see, and hear. That means the tools used to measure and analyze sales, market share and consumer behavior must also change. In an environment that continues to experience seismic shifts, measuring when, where and how consumers are buying is imperative. This allows fast-moving consumer goods (FMCG) manufacturers and retailers to anticipate trends and react faster to consumers’ needs and expectations. Although the fastest growing channel in Western Europe and North America is online, e-commerce measurement tools are largely fragmented. Users must combine data from multiple sources to get a full picture of the market. NielsenIQ is transforming the FMCG and retail industry with its innovative solutions and precise insights, which offer an integrated, accurate, complete, and more granular view of the offline and online marketplace—making it easier to analyze trends across channels. Our latest acquisiti

Proposed “European AI Act” and “Machinery Product Regulation” Will Hamper Innovation, Stifle Small Businesses and Disrupt Manufacturing, Global Robotics Leaders Warn8.12.2021 15:00:00 EET | Press release

The European Commission’s proposed AI Act and updated regulations on machinery products will cause severe damage to European small businesses, robotics companies and innovation, according to four of the most influential voices in robotics and automation. Together, the International Federation of Robotics, the VDMA Robotics + Automation Association, EUnited Robotics and REInvest Robotics urgently call on European policymakers to revisit and amend the proposals. While all four organizations embrace the European Commission’s vision to maintain safety, protect human rights and create a harmonized framework for artificial intelligence and robotics, the collective sees the following primary issues with the proposed regulations as currently drafted: The mandatory third-party certification requirements will slow tech innovation across Europe. The restrictions will hinder artificial intelligence adoption and put European companies, especially SMEs and startups, at a competitive disadvantage glo

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)8.12.2021 15:00:00 EET | Press release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID). The manuscript is available online and will be included in a future print edition of CID, the official peer-reviewed journal of the Infectious Diseases Society of America.1 The SOLSTICE study primary endpoint was met, with 55.7% (131/235) of adult patients on LIVTENCITY achieving confirmed CMV DNA level below the lower limit of quantification (<LLOQ, i.e. <137 IU/mL) at the end of Study Week 8 (end of treatment phase) in comparison with 23.9% (28/117) of patients on conventional antiviral therapies (one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir); adjusted difference [95% CI]: 32.8% [22.80 to 42.74]; P<0.001.1* The key secondary e

Deutsche Post DHL Group Begins Transition at the Top: Tobias Meyer, P&P Germany Ceo, to Become Group CEO in May 20238.12.2021 14:22:00 EET | Press release

Deutsche Post DHL Group has initiated the leadership transition at the top of the company. The Supervisory Board of Deutsche Post AG has extended Frank Appel’s contract as DPDHL Group CEO until May 4, 2023. His previous contract runs until October 31, 2022. Appel will continue to serve as DPDHL Group CEO until the Annual General Meeting in 2023. Thereafter, Tobias Meyer, will take over as DPDHL Group CEO. Meyer joined the company in 2013 and has held a wide variety of positions including Head of Corporate Development, Chief Operations Officer at DHL Global Forwarding, and Head of Operations and IT at Post & Parcel Germany. He has been CEO of Post & Parcel Germany and a member of the DPDHL Management Board since March 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005516/en/ Tobias Meyer, CEO Post & Parcel Germany (Photo: Business Wire) “In Tobias Meyer we have a recognized expert of the company taking over as DPD

 Aleph Farms and WACKER Develop Open Supply Chain Solution for Proteins Used in Large-Scale Production of Cultivated Meat8.12.2021 14:09:00 EET | Press release

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells and WACKER, a supplier of leading protein production technologies, today announced the development of streamlined production processes for essential growth medium proteins to cost-effectively grow cultivated meat. These proteins, central to promoting and supporting cell growth, are not widely available in the market today and represent one of the most prohibitive expenses in scaling up cultivated meat. The agreement between WACKER and Aleph Farms is non-exclusive, meaning any cultivated meat company will be able to obtain these same affordable proteins, without using fetal bovine serum (FBS) or animal-derived ingredients. This open supply chain solution is expected to enable the industry to scale and achieve price-parity faster, eliminating a key hurdle in the commercial viability of cultivated meat. "Bringing down the cost and making suitable raw materials available at t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom